{"result": "(\"entity\"<|>FEOCROMOCITOMA<|>EVENT<|>Feocromocitoma is a tumor that secretes catecholamines and requires surgical treatment after proper medical preparation.)\n##\n(\"entity\"<|>PARAGANGLIOMA<|>EVENT<|>Paraganglioma is a type of tumor related to feocromocitomas, which can also be malignant and may require surgical intervention.)\n##\n(\"entity\"<|>MEN2<|>EVENT<|>Neoplasia endocrina múltiple tipo 2 (MEN2) is an autosomal dominant disorder associated with feocromocitomas and other endocrine tumors.)\n##\n(\"entity\"<|>SDHB<|>EVENT<|>Mutations in the SDHB gene are linked to a higher risk of malignant feocromocitomas and paragangliomas.)\n##\n(\"entity\"<|>DÍAZ PÉREZ JA<|>PERSON<|>Díaz Pérez JA is an author referenced in the context of feocromocitomas and paragangliomas.)\n##\n(\"entity\"<|>CRESPO HERNÁNDEZ I<|>PERSON<|>Crespo Hernández I is an author referenced in the context of feocromocitomas and paragangliomas.)\n##\n(\"entity\"<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>ORGANIZATION<|>Harrison's Principles of Internal Medicine is a medical textbook that includes information on feocromocitomas.)\n##\n(\"entity\"<|>ENDOCRINE SOCIETY<|>ORGANIZATION<|>The Endocrine Society is an organization that provides clinical practice guidelines for the diagnosis and treatment of feocromocitomas and paragangliomas.)\n##\n(\"relationship\"<|>FEOCROMOCITOMA<|>MEN2<|>Feocromocitomas are frequently associated with neoplasia endocrina múltiple tipo 2 (MEN2)<|>7)\n##\n(\"relationship\"<|>FEOCROMOCITOMA<|>SDHB<|>Mutations in the SDHB gene can lead to malignant feocromocitomas<|>8)\n##\n(\"relationship\"<|>PARAGANGLIOMA<|>SDHB<|>Mutations in the SDHB gene are also linked to paragangliomas<|>8)\n##\n(\"relationship\"<|>DÍAZ PÉREZ JA<|>FEOCROMOCITOMA<|>Díaz Pérez JA authored a manual discussing feocromocitomas<|>6)\n##\n(\"relationship\"<|>CRESPO HERNÁNDEZ I<|>FEOCROMOCITOMA<|>Crespo Hernández I authored a manual discussing feocromocitomas<|>6)\n##\n(\"relationship\"<|>ENDOCRINE SOCIETY<|>FEOCROMOCITOMA<|>The Endocrine Society provides guidelines for the management of feocromocitomas<|>7)\n##\n(\"relationship\"<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>FEOCROMOCITOMA<|>Harrison's Principles of Internal Medicine includes information on feocromocitomas<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: through: Apr. 2019.\n\n## 27 En relación con el manejo preoperatorio de los feocromocitomas, indique cuál de las siguientes afirmaciones es correcta:\n\nA. Pacientes normotensos y asintomáticos no precisan preparación farmacológica.\nB. La preparación farmacológica debe iniciarse el día anterior a la intervención quirúrgica.\nC. El bloqueo betaadrenérgico debe iniciarse una vez que se ha instaurado el bloqueo alfaadrenérgico.\nD. Los bloqueantes de los canales de calcio están contraindicados en el manejo preoperatorio de esta patología.\n\nCOMENTARIO\n\nUna vez que el tumor secretor de catecolaminas ha sido diagnosticado, su tratamiento de elección es quirúrgico, pero es necesario realizar una preparación médica adecuada en todos los pacientes. El tratamiento preoperatorio incluye siempre un control adecuado de las crisis hipertensivas y una adecuada expansión de volumen. El bloqueo alfaadrenérgico debe iniciarse 10 a 14 días antes de la cirugía, siendo la fenoxibenzamida el tratamiento de elección. No puede olvidarse que el bloqueo betaadrenérgico nunca puede iniciarse en primer lugar para no exponer al paciente a mayores niveles de catecolaminas sobre los receptores alfaadrenérgicos y provocarle crisis hipertensivas.\n\n## 28 Respecto a los feocromocitomas, ¿cuál de las siguientes afirmaciones es cierta?\n\nA. El feocromocitoma maligno es frecuente (más del 20% en la mayor parte de las series) en la neoplasia endocrina múltiple tipo 2 (MEN2).\nB. El feocromocitoma maligno es frecuente (más del 20% en la mayor parte de las series) en las mutaciones de SDHB.\nC. Los antidepresivos tricíclicos pueden producir comúnmente falsos negativos en la medición de las metanefrinas.\nD. Las tres respuestas son falsas.\n\nCOMENTARIO\n\nAproximadamente, el 10% de los feocromocitomas y hasta un 20-25% de los paragangliomas son malignos. Se considera maligno cuando produce invasión local, metástasis a distancia o recurrencias, lo cual puede ocurrir hasta 20 años tras la resección del tumor.\n\nLas mutaciones en el gen SDHB dan lugar a enfermedad metastásica hasta en el 40% de los casos.\n\nLa neoplasia endocrina múltiple tipo 2-A es un trastorno autosómico dominante con penetrancia relacionada con la edad. El fenotipo MEN2A incluye el feocromocitoma suprarrenal (habitualmente bilateral y que puede ser asíncrono), el carcinoma medular de tiroides y el hiperparatiroidismo primario.\n---\nSUPRARRENALES 5\n\nAunque se prefiere que los pacientes no reciban ninguna medicación durante la evaluación diagnóstica, se puede continuar el tratamiento con la mayoría de los fármacos. Los antidepresivos tricíclicos interfieren con mayor frecuencia en la interpretación de catecolaminas y metanefrinas en orina de 24 horas (aumentan su valor) y se recomienda disminuir la dosis o suspender por lo menos 2 semanas antes de las pruebas hormonales.\n\nLas mutaciones en SDHD, SDHAF2 y SDHC son típicas de los paragangliomas de cabeza y cuello y están sujetas por el fenómeno de impronta materna (si la mutación es heredada de la madre no se manifiesta y tiene alta penetrancia si se hereda del padre). Los pacientes con mutaciones en SDHB presentan más a menudo paragangliomas en tórax y abdomen y en hasta un 50% de los casos metástasis a distancia.\n\nUn hallazgo interesante en relación con el tipo de mutaciones en SDHB y SDHD es que las mutaciones de sentido erróneo o missense son relativamente más frecuentes que las mutaciones que producen un codón de parada y dan lugar a una proteína truncada en SDHB, mientras que en SDHD son más frecuentes las mutaciones que producen una proteína truncada.\n\nReferencias:\n- Díaz Pérez JA, Crespo Hernández I. Feocromocitoma y paraganglioma. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es (última modificación: 24 de noviembre de 2015).\n- Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99:1915-41.\n- Neumann HPH. Feocromocitoma. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison Principios de Medicina Interna. 19.ª\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}